Safety and Efficacy of LCL161 in Patients With Solid Tumors

Inclusion Criteria: * Solid tumor * ECOG performance status 0-2 * Life expectancy greater than or equal to 12 weeks * Must meet certain blood laboratory values * Must meet criteria for time since the last dose of prior therapy * Must provide written informed consent to participate in this study Exclusion Criteria: * Active and/or symptomatic brain tumors or brain metastases. * Patients with unresolved nausea, vomiting, or diarrhea * Any ongoing severe and/or uncontrolled medical condition that could compromise participation in the study including heart, lung or inflammatory disease * Any disease that may significantly alter the absorption of the study drug (for example, ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or removal of small bowel) * Patients who are currently receiving treatment with steroids at a certain dose or other immunosuppressive treatment that cannot be stopped prior to starting study drug * Patients who are currently receiving treatment with certain medications * Patients who have received radiation therapy or have undergone major surgery within the last 4 weeks * Women of child-bearing potential who are pregnant or breast feeding. * Known diagnosis of human immunodeficiency virus (HIV) infection or chronic active hepatitis B or C * Patients unwilling or unable to follow the protocol Other protocol-defined inclusion/exclusion criteria may apply